Nebenwirkungen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 22
HOS-138535 · Präparat HOS-098200
The safety of the components of Symtuza was also evaluated in a limited number of children aged 6 to < 12 years, weighing at least 25 kg to < 40 kg through the clinical study GS-US-216-0128 (N = 9, with 24 weeks follow-up) for cobicistat-boosted darunavir (DRV/COBI) with emtricitabine/tenofovir alafenamide (F/TAF). The data from these studies showed that the overall safety profile of the components of Symtuza in paediatric patients aged 6 to < 18 years weighing at least 25 kg was consistent with that observed in the adult population (see section 5.1).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage f49f7f8f7e580e8390af15687fbeea7806a1971715288419024d036735635588 · Zeichen 10200–10757 im Abschnitt